Oncolytics Biotech Files April 2024 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Apr 30, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
Related Tickers: ONCY
TL;DR
Oncolytics Biotech (ONCY) filed its April 6-K, standard foreign private issuer update.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on April 30, 2024, reporting as a foreign private issuer for the month of April 2024. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing indicates they are submitting their report under the 1934 Securities Exchange Act.
Why It Matters
This filing provides an update on Oncolytics Biotech's reporting status as a foreign private issuer, which is standard for companies with international operations and listings.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would immediately impact the company's risk profile.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the 6-K report
- 001-38512 (company) — SEC File Number for Oncolytics Biotech Inc.
- 20240430 (date) — Filing date and period of report
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer of this report?
The filer is Oncolytics Biotech Inc.
What is the filing date?
The filing date is April 30, 2024.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc. is located in Calgary, Alberta, Canada.
Under which SEC Act is this report filed?
This report is filed pursuant to the Securities Exchange Act of 1934.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-04-30 16:42:35
Filing Documents
- form6kq1-2024date.htm (6-K) — 18KB
- oncyq12024date.htm (EX-99.1) — 11KB
- 0001129928-24-000029.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date April 30, 2024 Kirk Look Chief Financial Officer